Search results
Showing 256 to 270 of 2581 results for methods
In development Reference number: GID-TA10326 Expected publication date: TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]
In development Reference number: GID-TA10223 Expected publication date: TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]
In development Reference number: GID-TA10225 Expected publication date: TBC
In development Reference number: GID-TA10227 Expected publication date: TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
In development Reference number: GID-TA10573 Expected publication date: TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
In development Reference number: GID-TA10623 Expected publication date: TBC
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.
This interim process statement has been produced to guide the development of good practice guidance. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.
This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.
View quality statements for QS178Show all sections
Sections for QS178
- Quality statements
- Quality statement 1: Asking people about their sexual history
- Quality statement 2: Discussing prevention and testing with people who are at risk of sexually transmitted infections
- Quality statement 3: Condom distribution schemes
- Quality statement 4: Access to sexual health services
- Quality statement 5: Repeat testing for sexually transmitted infections
- Quality statement 6: Partner notification
- Update information
Recommendation ID NG135/6 Question What methods and techniques help secondary schools and providers to effectively engage with parents
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.
ID6611 Obesity, overweight - semaglutide (including review of TA875)
Awaiting development Reference number: GID-TA11851 Expected publication date: TBC
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.